Observational Study of Iron Metabolism Markers and Their Link to Calcium, Liver Function, and Inflammation in Adults on Hemodialysis

What this Trial Is About

Researchers are studying how iron is absorbed, metabolized, eliminated, and stored in the body during advanced kidney failure. The focus is on understanding how hormones that regulate iron interact with calcium, phosphate, liver metabolism, and inflammation in patients undergoing hemodialysis. The main goal is to monitor the levels of two key biomarkers, hepcidin and erythroferrone, which are important in iron metabolism but not routinely measured in dialysis centers. This observational study involves hemodialysis patients who will have blood samples taken to track changes in hepcidin and erythroferrone levels over time. Each blood draw collects 15 mL to measure these markers. The study does not involve any treatment but observes the natural progression and relationships between iron metabolism and other body processes in these patients. Participants will be followed for five years, during which the concentration of hepcidin and erythroferrone will be regularly measured through blood tests. The study will also consider links with calcium phosphate metabolism, liver function, and inflammation. Patients will provide written consent and undergo periodic assessments to help researchers understand how these markers evolve in the context of hemodialysis and related complications.

Study of Markers of Iron Metabolism and Their Relationship With Phosphocalcic and Hepatic Metabolism and Inflammation in Hemodialysis Patients